Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bth1704
- Development stage
- Discontinued
- Lead developer
- HiberCell
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BTH1704 is a humanized IgG1 monoclonal antibody designed for intravenous administration. It targets aberrantly glycosylated Mucin 1 (MUC1), a protein overexpressed and abnormally glycosylated in various cancers. The drug exerts its antitumor effects primarily through antibody-dependent cell cytotoxicity and immunostimulation by binding to MUC1 on the surface of cancer cells, leading to opsonization and immune-mediated destruction of tumor cells. Originally based on the murine monoclonal antibody HMFG1, BTH1704 was developed as an antineoplastic agent for solid tumors such as breast and pancreatic cancer. Its development has been discontinued for breast cancer after clinical trials failed to progress beyond early phases; phase 1 trials in pancreatic cancer were also terminated[1][2][7].
- Brand names
- Therex
- Other names
- Monoclonal antibody HMFG1Therex
02
Targets
MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on bth1704.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bth1704.